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Abstract
The ability to observe changes in molecular behavior during cancer cell invasion in vivo remains a
major challenge to our understanding of the metastatic process. Here, we demonstrate for the first
time an analysis of RhoA activity at a subcellular level using FLIM-FRET imaging in a live
animal model of pancreatic cancer. In invasive mouse pancreatic ductal adenocarcinoma (PDAC)
cells driven by mutant p53 (p53R172H), we observed a discrete fraction of high RhoA activity at
both the leading edge and rear of cells in vivo which was absent in two-dimensional in vitro
cultures. Notably, this pool of active RhoA was absent in non-invasive p53(fl) knockout PDAC
cells, correlating with their poor invasive potential in vivo. We used dasatanib, a clinically
approved anti-invasive agent that is active in this model, to illustrate the functional importance of
spatially regulated RhoA. Dasatanib inhibited the activity of RhoA at the poles of p53R172H cells
in vivo and this effect was independent of basal RhoA activity within the cell body. Taken
together, quantitative in vivo fluorescence life-time imaging illustrated that RhoA is not only
necessary for invasion, but that subcellular spatial regulation of RhoA activity, as opposed to its
global activity, is likely to govern invasion efficiency in vivo. Our findings reveal the utility of
FLIM-FRET in analyzing dynamic biomarkers during drug treatment in living animals, and they
also show how discrete intracellular molecular pools might be differentially manipulated by future
anti-invasive therapies.
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Introduction
Coordinated activity of the RhoGTPases RhoA, Rac1 and Cdc42 has been extensively
studied during cell motility and migration in vitro (1). RhoA is known to control
actomyosin-based contractility and retraction at the rear of the cell while Rac and Cdc42
regulate lamellipodia and filopodia formation at the front of the cell, respectively (2, 3). The
ability to visualize the precise spatial and temporal activity of RhoGTPase family members
using fluorescent reporters in vitro has rapidly enhanced our understanding of their distinct
roles in cell motility (4-7). This approach has also provided an insight into their role in other
key biological processes and diseases such as cancer (4, 8, 9). Recently, several elegant
studies have focused on RhoA activity during the initial events of protrusion at the leading
edge and poles of cells in vitro (5, 10-12). In particular, using fluorescence resonance energy
transfer (FRET)-reporters of individual RhoGTPases simultaneously within the same cell,
RhoA activity was shown to synchronize with leading edge protrusion both spatially and
temporally (11). This, in combination with the recent manipulation of Rac1 and Cdc42
activity using light-switchable probes, has confirmed that RhoA activity plays a key role in
protrusion in addition to its previously reported role in cell retraction during cell motility
(12). Altered expression or activity of RhoA has been positively correlated with numerous
forms of human metastatic disease (8, 13-15), and taken with these novel findings regarding
RhoA activity at the cell poles during motility, prompted us to assess for the first time the
spatial regulation of RhoA activity during cancer cell invasion in live animals.
Pancreatic cancer is one of the most lethal forms of human cancer, with an overall 5-year
survival rate of less than 5% (16, 17). Initiating KRAS mutations occur in approximately
90% of human PDACs (18-20) while TP53 mutations arise in 50-75% of human pancreatic
cancers (21). Previously, we have utilized a recently developed mouse model of invasive
and metastatic pancreatic cancer (22) in which Cre-Lox technology is used to target
KrasG12D and mutant p53R172H to the mouse pancreas via the Pdx1 promotor. This results in
the formation of preinvasive pancreatic intraepithelial neoplasms (PanINs) which develop
into invasive and metastatic PDACs (22). Using this model, we have recently demonstrated
that mutations of Trp53, rather than loss of p53, drives invasion and metastasis in pancreatic
cancer, thereby indicating a gain-of-function role for the accumulation of mutant p53 (23).
Moreover, we and others have shown that mutant p53 drives invasion and metastasis in
cancers other than the pancreas, including colon, lung and breast cancer (24, 25). Recently,
cooperation between mutant p53 and oncogenic Ras has been shown to activate RhoA and
induce cell motility in vitro (26). In line with this, mutant p53 has also been shown to induce
the expression of the RhoA-specific guanine nucleotide exchange factor GEF-H1, a
regulator of RhoA activity at the leading edge and rear of the cell during motility in a large
number of cancer types, including the pancreas (27, 28).
As the KrasG12D/ p53R172H mouse model (22) recapitulates human pancreatic
tumourigenesis in terms of histopathology, disease progression and metastatic profile (29,
30), it provides an excellent system to examine for the first time the precise spatial
regulation of RhoA activity in an in vivo model of invasive pancreatic cancer. In order to
investigate the activity of RhoA, we initially established cells from invasive pancreatic
tumors of Pdx1-Cre, LSL-KRasG12D/+, LSL-Trp53R172H/+ mice and corresponding non-
invasive tumor cells from Pdx1-Cre, LSL-KRasG12D/+,Trp53LoxP/+ mice (23). From these
cells, we generated stable PDAC lines expressing a modified version of the Raichu-RhoA
FRET-reporter (4, 31). RhoA activity in individual cells within subcutaneous tumors was
then assessed using fluorescence life-time imaging microscopy (FLIM)-FRET in live
animals, allowing us to observe this phenomenon in a more physiological and functional
context. Importantly, we demonstrate spatially restricted pools of RhoA activity that are
specifically sensitive to drug treatment and correlate with invasion in vivo. This result, taken
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with our assessment of RhoA activity during organotypic invasion, demonstrates significant
differences in the sub-cellular spatial regulation of RhoA in three-dimensions compared to
standard two-dimensional culture models. Importantly, this work highlights the advantages
of live, sub-cellular, animal imaging in the assessment of invasion and metastasis and
demonstrates that FLIM-FRET imaging can be adapted for the in vivo assessment and
quantification of subtle, context-dependent responses to therapeutic intervention in the
treatment of cancer.
Materials and Methods
Cell culture
Primary mouse PDACs were derived from tumors harvested from Pdx1-Cre-GFP, LSL-
KRasG12D/+, LSL-Trp53R172H/+ mice and Pdx1-Cre-GFP, LSL-KRasG12D/+, Trp53LoxP/+
mice (23). Cell lines were tested 1 month before experiments and authenticated by
morphology, growth curve analysis, and Mycoplasma detection in accordance with the
ATCC cell line verification test recommendations and cultured as described in detail in SI
Materials and Methods.
Drug treatment in vitro and in vivo
Dasatinib (a kind gift from Bristol Myers Squibb) was administered daily by oral gavage in
80 mmol/L citrate buffer [10 mg/kg] or 100 nM in vitro (33). ROCK inhibitor Y27632
(Calbiochem) was used at 10 μM and cell permeable C3 Transferase (Cytoskeleton) was
used at 0.125 μg/ml.
Plasmids
For details of the modified GFP-RFP Raichu-RhoA reporter see SI Materials and Methods.
Organotypic invasion assay
Organotypic cultures were set up as described (32).
RhoA activity assay
GTP loading of RhoA was determined using a RhoA activation kit as described in
manufacturers protocol (cytoskeleton).
Imaging
All imaging was performed on a Nikon Eclipse TE2000-U inverted microscope with a
LaVision Biotec Trim-scope scan head. See SI Materials and Methods.
Fluorescence life-time imaging of RhoA FRET reporter in vitro and in vivo
For detailed procedure see SI Materials and Methods.
Data Analysis
Data was analyzed using the built-in TCSPC fluorescence lifetime analysis functionality of
ImSpectorPro (LaVison Biotec, Germany). See details in SI Materials and Methods.
Results and Discussion
Generation of a FLIM-FRET based genetic model of invasive pancreatic cancer
The use of FLIM to measure FRET reporters has rapidly enhanced our understanding of
various biological processes by allowing us to obtain a detailed picture of protein behavior
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both spatially and temporally in vitro (34, 35). In order to study RhoA activity during
pancreatic cancer cell invasion in vivo, we first established primary invasive pancreatic
tumor cell lines from Pdx1-Cre, LSL-KRasG12D/+, LSL-Trp53R172H/+ mice and non-
invasive pancreatic tumor cell lines from Pdx1-Cre, LSL-KRasG12D/+, Trp53LoxP/+ mice
(23). Using these cells we then generated stable PDAC cell lines expressing a GFP-RFP
variant of the Raichu-RhoA FRET-reporter (Fig. 1A) (4, 31). The resulting invasive mutant
p53R172H and non-invasive p53fl PDAC cells expressing the RhoA-reporter with a common
initiating KrasG12D/+ mutation (22) serve as an excellent genetic and fluorescent model
system to directly compare the spatial regulation of RhoA activity in pancreatic cancer.
To examine the maximum dynamic range of the adapted Raichu-RhoA probe in its ‘open’
(inactive) or ‘closed’ (active) state we performed fluorescence life-time measurements in
both invasive mutant p53R172H and non-invasive p53fl PDAC cells expressing both the
dominant negative (T19N) and constitutively active (Q63L) versions of the probe (4).
Transient over-expression, in both PDAC cell lines, of the T19N mutant which reduces the
affinity of the probe to guanine nucleotides, resulted in a maximum inactive life-time of
2.2-2.3 ns (Fig. 1B). In contrast, transient over-expression of the Q63L GTPase-deficient
mutant probe resulted in a maximum active life-time of 1.7-1.8 ns in both PDAC cell lines
(Fig. 1B).
To assess the range of fluorescence life-time of the probe with known biochemical
inactivation or activation, we serum starved cells for 48 hours to reduce RhoA activity and
subjected cells to biochemical stimulation (see supplementary Fig. 1). Low, basal RhoA
activity, is represented in the life-time color maps with red/yellow colors, while high RhoA
activity is represented as blue colors and areas with a low signal to noise ratio in which a
life-time measurement cannot be achieved are black. Stimulation with known RhoA
activators such as lysophosphatidic acid (LPA) or calpeptin significantly activated the probe
globally giving an average life-time of approximately 1.8 ns and 1.9 ns respectively (see
supplementary Fig. 1A-C with accompanying life-time color maps and Rhotekin pull-down
assay), while addition of cell-permeable C3 transferase resulted in the probe remaining in
the inactive state (see supplementary Fig. 1A) (1, 36). Finally, in line with this, over-
expression of a constitutively active RhoGEF, onco-Lbc (37), also significantly activated the
RhoA reporter globally within the cell resulting in an average life-time of 1.7-1.8 ns (see
supplementary Fig. 1A).
To assess whether fluorescence life-time imaging could be used to rapidly and accurately
detect subtle changes in RhoA activity, invasive mutant p53R172H PDAC cells were initially
subjected to wound heal assays in which the activity of RhoA in individual cells at the
leading edge of the wound was compared to confluent cells at the rear within different time
frames. At early time points after wounding, small sub-populations of cells proximal to the
wound edge showed significant activation of RhoA activity, as determined by low
fluorescence life-time measurements resulting from FRET of the RhoA reporter (Fig. 1C,
white arrows indicate active cells with a fluorescence life-time of approximately 1.8-1.9 ns
which appear blue on the life-time color map). In contrast, cells at the rear of the wound had
a low basal level of activity (Fig. 1D, red arrows and quantified in Fig. 1E). Importantly,
using a Rhotekin-based RhoA-GTP pull down assay, the difference in RhoA regulation at
the wound edge could not be detected when only one scratch wound was performed (Fig.
1F). Only when multiple wounds where performed was the activation of RhoA apparent in
the Rhotekin-based pull down assay (Fig. 1F), demonstrating the advantages of single-cell
fluorescence life-time imaging over standard biochemical techniques in which these effects
may be masked.
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The specific activation of RhoA in cells at the wound edge suggests that a gradient of RhoA
activity may exist within the local environment of migrating tumors. In line with this,
differential activity or expression of key proteins at the invasive edge of tumors, or in ‘hot
spots’ within a tumor population in vivo, have previously been demonstrated using
immunohistochemical staining of fixed tumor sections (33, 38). Consistent with this, using
FRAP or photoactivation, we have recently demonstrated in vivo that E-cadherin-based
junctions and plasma membrane dynamics, both of which play vital roles in invasion, are
also locally regulated by different environmental cues within the tumor cell population (39).
Using FLIM-FRET to assess protein behavior in individual cells, within living animals,
during invasion would therefore provide a more detailed understanding of cell activity
during this process and may ultimately contribute to the development of novel targeted anti-
invasive drug therapies.
Spatial regulation of RhoA activity during three-dimensional organotypic pancreatic
cancer invasion
Invasion in complex three-dimensional matrices that mimic in vivo conditions, such as
organotypic assays, has revealed distinct modes of cell locomotion adopted by cancer cells
that are governed by both the surrounding stromal cells and the density and topography of
the extracellular matrix (40, 41). To determine whether RhoA plays a role in mutant
p53R172H-driven pancreatic cancer cell invasion (23, 27, 28) we examined PDAC cell
invasion in a three-dimensional organotypic model. We established organotypic cultures of
primary human fibroblasts and rat tail fibrillar collagen I (32, 40), which when exposed to an
air/liquid interface creates a chemotactic gradient that induces invasion of overlayed cancer
cells (see supplementary movie 2, cancer cells in green invading over fibroblasts in red).
The invasion of mutant p53R172H or p53fl PDAC cells was assessed over an 8-12 day period,
in combination with multiphoton-based second harmonic imaging of the surrounding
extracellular matrix (ECM) (see supplementary movies 3-5, cancer cells in green, ECM
appears purple). Consistent with our recent in vivo data (23), we observed that mutant
p53R172H PDAC cells degrade and collectively invade into the matrix, while p53fl PDAC
cells remained on top of the matrix surface (Fig. 2A,B). Quantification of the percentage of
total PDAC cells in the organotypic assay that invade beyond 30 μm as a ratio of cells on
top by H&E staining confirmed that expression of mutant p53R172H confers the capacity for
PDAC cells to invade over time, while p53fl cells do not invade (Fig. 2C). Importantly,
inhibition of ROCK, the downstream effector of RhoA, using the inhibitor Y27632
significantly reduced the invasion of mutant p53R172H PDAC cells in the organotypic assay
at both 8 and 12 days of invasion (Fig. 2C and supplementary Fig 6). Similar results were
observed upon treatment with cell-permeable C3 transferase, suggesting that activation of
the RhoA pathway plays a critical role in pancreatic cancer cell invasion (Fig. 2C). A similar
induction of invasion was observed when the human equivalent of murine p53R172H
(p53R175H) was expressed in p53 null PDAC cells (Fig. 2D, E and quantified in 2F)
To specifically investigate a role for RhoA during invasion, we accurately measured RhoA
activity using FLIM-FRET at day zero and day 8 of organotypic invasion. Fluorescence life-
time imaging of p53fl cells on the matrix surface revealed a weak basal activity of RhoA at
day zero (Fig. 3D, column 1) and when exposed to a chemotactic gradient for 8 days, failed
to activate RhoA above basal levels (Fig. 3A and quantified in 3D, column 2), correlating
with the absence of cell invasion (Fig. 2A). Similarly, over a longer time course of up to 21
days (see supplementary Fig. 7), these cells did not invade, consistent with in vivo data (23).
In contrast, fluorescence life-time imaging of mutant p53R172H PDAC cells on the matrix
surface revealed an initial weak basal activity of RhoA at day zero (Fig. 3D, column 3),
however when exposed to a chemotactic gradient for 8 days, cells on the matrix surface
exhibit significant RhoA activation (Fig. 3B and quantified in 3D, column 4).
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Multiphoton-based FLIM-FRET provides the potential to image RhoA activity at greater
penetration depths (42), however previous detection efficiencies have been a limiting factor
in the use of FLIM-FRET for three-dimensional investigations. To overcome this limitation,
we have utilized a multi-channel TCSPC PMT as a non-descanned detector (see Materials
and Methods) allowing for accurate detection and measurement of fluorescence life-times at
a depth of ~ 150 μm within an organotypic matrix (Fig. 2B, red arrows depict examples of
cells analyzed by FLIM-FRET at depth). Analysis of RhoA activity up to 150 μm within the
matrix (Fig. 3C), demonstrated that actively invading mutant p53R172H cells have an
enhanced average activity of RhoA compared to those present on the matrix surface
(quantified in Fig. 3D, column 5). A similar increase in RhoA activity at ~ 150 μm was also
observed over a longer time course of up to 12 days of invasion (see supplementary Fig. 8).
Interestingly, in the majority of invading mutant p53R172H cells we observed a discrete
fraction of active RhoA at the pole of the cells (Fig. 3C, white arrow and quantified in 3E).
Significantly, we did not observe this sub-cellular spatial regulation of RhoA activity within
cells in two-dimensional culture at the rear or front of migrating cells (Fig. 1C,D). This
suggests that in a three-dimensional context, RhoA may be spatially regulated at the poles of
mutant p53R172H cells to drive protrusion.
Fluorescence life-time imaging of RhoA activity in a live animal microenvironment
Our ability to use fluorescence life-time imaging at depth to assess RhoA activity in three-
dimensions and the added contextual detail this provides, prompted us to investigate whether
we can assess RhoA activity under more native physiological conditions in live animals.
Imaging invasion in a live animal setting is inherently difficult due to sample instability,
autofluorescence, poor tissue penetration and light scattering (40, 43, 44). Recent advances
in multiphoton microscopy as described here, however, have improved both the resolution
and imaging depth thereby providing a powerful tool for directly observing key events in the
invasive and metastatic process in situ. PDAC cells were therefore grown as subcutaneous
tumors in nude mice and the ability of multiphoton-based FLIM to measure activity of the
RhoA reporter within tumor tissue was examined (see Materials and Methods). The added
sensitivity of a multi-channel TCSPC PMT detector allowed us to detect the activity of
RhoA up to ~150 μm within solid tumor tissue, allowing cells completely surrounded by
ECM, stroma and vasculature to be readily assessed in vivo.
The fluorescence life-time of the RhoA reporter in PDAC cells was quantified in vivo at
different sites within the tumor. Consistent with our data showing that loss, as compared
with mutation, of p53 in the pancreatic mouse model results in non-invasive PDAC cells
(supplementary Fig. 9 and (23)), we observed low RhoA activity in p53fl cells in vivo (Fig.
4A). In contrast, we found a geometrically distinct sub-cellular fraction of active RhoA at
the poles of invasive mutant p53R172H PDAC cells in vivo (Fig. 4B white arrows and inset
compared to Fig. 4A white arrows and inset). Quantification of the sub-cellular distribution
within the cell body and poles confirmed that the spatial regulation of RhoA activity was
only exhibited by invasive mutant p53R172H PDAC cells and not p53fl cells (Fig. 4C). This
result suggests that the fraction of active RhoA at the poles of cells in vivo may contribute to
invasion. This observation is consistent with recent work in zebra fish, by Kardash and
colleagues, where RhoA was shown to drive protrusion in polarized germ-cells at the
leading edge during embryonic development (9).
In vivo spatial regulation of RhoA activity in invasive mutant p53R172H PDAC cells upon
treatment with the anti-invasive drug dasatinib
Using a genetically engineered GFP pancreatic cancer model Pdx1-Cre-GFP, LSL-
KRasG12D/+, LSL-Trp53R172H/+ to image invasion and metastasis in vivo (33) we have
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recently shown that therapeutic intervention with dasatinib, a clinically approved anti-
invasive Src inhibitor, significantly impairs metastatic burden in these mice (33). This,
together with previous work by our group showing the reciprocal relationship between
RhoGTPases and Src kinase activity during polarized cell motility (45) prompted us to
assess the effect of dasatinib treatment on RhoA activity in the invasive mutant p53 PDACs
both in organotypic assays and in live animals. Dasatinib treatment in the organotypic assay
significantly reduced both murine p53R172H and human p53R175H-driven PDAC cell
invasion (Fig. 5A and B), consistent with our previous finding in vivo (33). We therefore
went on to investigate the effect of dasatinib on invasive mutant p53R172H PDACs in a live
animal setting. Mice bearing subcutaneous PDAC tumors were treated with 10 mg/kg of
dasatinib (33, 39) for 3 days prior to fluorescence life-time imaging of RhoA activity in
conjunction with second harmonic imaging of the host ECM (Fig. 6A and C shows cells in
green and ECM by second harmonic imaging in purple; supplementary Fig. 10 shows
dasatinib-mediated inhibition of Src activity in vivo by immunoblotting). Strikingly, while
the polarized and protrusive morphology of mutant p53R172H PDAC cells remained present
upon dasatinib treatment (compare green fluorescence images in Fig. 6A and C, white
arrows), the sub-cellular pool of RhoA activity at the front and rear of cells, as determined
using FLIM, was inactivated (compare fluorescence life-time images Fig. 6B and D, white
arrows and insets). Quantification confirmed that while basal RhoA activity within the cell
body of mutant p53R172H PDAC cells was not affected, dasatinib treatment specifically
inactivated RhoA activity at the poles of cells in vivo (Figure 6E). Whether this polar RhoA
activity is driving contraction, protrusion or both in vivo is currently unknown. This
however could be addressed in the future by simultaneously imaging protrusion and
contraction in live animals with real-time FLIM-FRET (5, 11). Moreover, it is also possible
that this spatially localized inhibition may affect cell adhesion/interaction with the
surrounding ECM components in vivo as both impairment of RhoA and Src have previously
been shown to play key roles in adhesion dynamics (1, 8, 45, 46). This could therefore
partially explain the reduced invasive and metastatic efficiency found in dasatinib treated
mice and therefore warrants further investigation in the future (33).
As we have shown, fluorescence life-time imaging allows the differential regulation of
protein activity within a tumor cell population to be individually assessed (Fig. 1).
Consistent with this, we find that not all cells in vivo treated with dasatinib are inactive (Fig.
6F). Approximately 80% of mutant p53R172H cells, examined using FLIM, exhibited RhoA
activity in control mice and upon dasatinib treatment we observe that approximately 20% of
cells remain active within the tumors, independent of drug treatment (Fig. 6F). This is likely
to be due to critical differences within the solid tumor cell mass, for example due to poor
vasculature or limited perfusion and access of the drug to key areas of the tumor (47). In this
regard, recent exciting work has addressed the role tumor-associated matrix and stromal
tissue plays in pancreatic cancer drug delivery (48). Using the mutant p53R172H mouse
model described here, combination therapy to deplete tumor-associated matrix and improve
vasculature using the Hedgehog inhibitor IPI-926 was shown to improve the delivery and
efficacy of chemotherapeutic drug treatment to solid tumors (48). As the small fraction of
active cells that we observe may progress and form micro-metastases after initial therapeutic
intervention and/or tumor resection, it would be beneficial to pin-point areas of poor drug
delivery within different tumor micro-environments using FLIM-FRET in the future.
The adaptation of two-dimensional fluorescence techniques for intravital imaging has
resulted in a new era of context-dependent in vivo imaging, providing a greater picture of
key biological events in situ (39, 42, 43, 49). Here we have demonstrated the first use of
FLIM-FRET to monitor molecular dynamics of RhoA in tumors upon therapeutic
intervention. In doing so, we have specifically isolated at a sub-cellular level a small yet
important pool of RhoA, not observed in vitro, that is sensitive to drug treatment and
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correlates with invasion. These differences have implications for cancer research, in which
the behavior of key molecules associated with motility, invasion and metastasis in vitro are
used to reveal basic biological mechanisms which are then extrapolated back into the human
disease (39, 50). Such detailed topological analysis in vivo enables the detection of subtle
changes in protein activity following therapeutic interventions that are intractable to in vitro
assessment and could improve the current high attrition rate of compounds entering clinical
trials in the future (50).
The distinct sub-cellular regulation of RhoA at the poles of invading cells observed here sets
a precedent that other key RhoGTPases or proteins involved in invasion may also be tightly
regulated in such a manner in vivo. The use of this technique for the assessment of other
prototypical Rho family GTPases, including Rac and Cdc42, could therefore provide insight
into their coordinated regulation in vivo not only during invasion and metastasis, but also in
the context of other biological processes such as transformation, cell cycle progression,
transcriptional activation and response to drug treatment (1, 15, 45). Also, as described
earlier, Rho GEFs, GAPs and GDIs act as integrated upstream ‘molecular switches’, critical
for control of RhoGTPases, and are commonly mutated or aberrantly regulated in many
cancer types including the pancreas (8). The use of FLIM to measure FRET reporters, in
conjunction with the assessment of altered Rho-signaling components, could allow us to
investigate whether global or site-specific deregulation of RhoGTPase activity contributes to
these cancer types.
Finally, we and others have recently shown that mutant p53 drives invasion and metastasis
in pancreatic, colon, lung and breast cancer (24, 25) and that altered regulation of cell-ECM
interactions via integrins seems to play a central role in driving invasion (24). As RhoA is
involved in integrin inside-out and outside-in signaling (46), investigation of RhoA activity
in these mutant p53-driven cancers should provide a new level of detail regarding the
regulation of RhoA during cell-ECM interactions in the course of invasion in vivo as a
potential effector of mutant p53.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Fluorescence life-time imaging of RhoA activity within a migrating pancreatic tumor cell
population during wound healing. A, Schematic of the adapted GFP-RFP Raichu-RhoA
reporter adapted from Yoshizaki et al (4). B, Quantification of life-time measurements in
p53fl or p53R172H PDAC cells transiently transfected with dominant negative (T19N) or
constitutively active (Q63L) mutants of the Raichu-RhoA reporter. C, D Representative
fluorescence image of p53R172H PDAC cells expressing the Raichu-RhoA reporter (green)
at the front or rear of a wound with corresponding life-time maps of RhoA activity. White
arrows depict active cells. E, Quantification of life-time measurements of RhoA activity for
cells at the front or rear of the wound. Cells were classed to be at the front of the wound
within the first three cells from the wound border. F, Anti-Rho immunoblot of total cell
lysate and GST-Rhotekin ‘pulldown’ (GTP-Rho) from confluent versus single or multiple
wounded p53R172H PDAC cells. Columns, mean; bars, SE. **, P < 0.01
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Figure 2.
RhoA activity is required for PDAC invasion. A,B H&E-stained sections of p53fl and
p53R172H cells on organotypic matrix. C, Quantification of p53fl and p53R172H PDAC cell
invasion ± Y27632 or cell-permeable C3 in the organotypic matrix at 8, 12 days. D,E H&E-
stained sections of p53fl cells expressing vector or human mutant p53R175H cultured on
organotypic matrix. Quantification of human mutant p53R175H-driven PDAC invasion in the
organotypic matrix at 8 days. Red arrows depict examples of cells assessed at depth for Fig.
3C. Columns, mean; bars, SE. **, P < 0.01
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Figure 3.
Spatial regulation of RhoA activity during invasion. A-C, Representative fluorescence
images of p53fl and p53R172H cells expressing the Raichu-RhoA reporter (green) on the
matrix surface or during invasion with corresponding life-time map of RhoA activity. D,
Quantification of life-time measurements of RhoA activity at 0 (dashed columns) and 8 days
for cells on and within the matrix surface for both p53fl and p53R172H PDAC cells,
respectively. E, Percentage of p53R172H PDAC cells demonstrating distinct RhoA activity at
the poles of cells within the three-dimensional matrix. White arrow demonstrates distinct
RhoA activity at the pole of the cell. Columns, mean; bars, SE. **, P < 0.01
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Figure 4.
Spatial regulation of RhoA activity in live animals. A,B Representative in vivo fluorescence
images of p53fl and p53R172H PDAC cells expressing the Raichu-RhoA reporter (green)
with corresponding in vivo life-time map of RhoA activity, respectively. C, Quantification
of life-time measurements of RhoA activity within the cell body or poles of p53fl and
p53R172H PDAC cells in live animals as indicated. Columns, mean; bars, SE. **, P < 0.01
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Figure 5.
Dasatinib inhibits mutant p53-driven PDAC cell invasion. A,B H&E-stained sections and
quantification of mutant p53R172H or p53R175H -driven PDAC cell invasion ± dasatinib in
the organotypic matrix at 8-12 days. Columns, mean; bars, SE. **, P < 0.01
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Figure 6.
Spatial regulation of RhoA activity in invasive p53R172H PDAC cells upon dasatinib
treatment in vivo. A and C, Representative in vivo fluorescence images of mutant p53R172H
PDAC cells expressing the Raichu-RhoA reporter (green) with SHG signal from host ECM
components (purple). B and D, Corresponding in vivo life-time maps demonstrating the
presence and absence of RhoA activity in sub-cellular polar regions of cells ± dasatinib,
respectively. E, Quantification of fluorescence life-time measurements of RhoA activity
within the cell body or poles of p53R172H cells ± dasatinib. (F) Distribution of active and
inactive polar regions in p53R172H PDAC cells within the tumor tissue ± dasatinib.
Columns, mean; bars, SE. **, P < 0.01
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